Bristol Myers Squibb (NYSE:BMY) today announced that new clinical and health economics and outcomes research data (HEOR) from its neuropsychiatry portfolio evaluating COBENFY (xanomeline and trospium chloride) in schizophrenia in adults will be presented at Psych Congress 2024, taking place October 29 – November 2 in Boston, Massachusetts.
"Building on momentum from the recent U.S. Food and Drug Administration's approval of COBENFY for the treatment of schizophrenia in adults, we're pleased to be sharing additional data at Psych Congress from the EMERGENT clinical trial program that further highlights the differentiated clinical profile of COBENFY, including efficacy, safety, and patient reported outcomes of adults with schizophrenia who participated in our long-term clinical trials," said Alyssa Johnsen, MD, PhD, senior vice president and head of clinical development, Immunology, Cardiovascular and Neuroscience, Bristol Myers Squibb. "As we continue to strengthen our neuropsychiatry portfolio, we remain committed to developing and delivering differentiated options for patients."
Research to be presented at the meeting continues to demonstrate COBENFY as a differentiated treatment option for adults living with schizophrenia. Notable data poster presentations include:
Clinical:
- Long-Term Safety and Efficacy of Xanomeline and Trospium Chloride in Schizophrenia: Results from the 52-Week, Open-Label EMERGENT-4 Trial
- Long-Term Safety, Tolerability, and Efficacy of Xanomeline and Trospium Chloride in People with Schizophrenia: Results From the 52-Week, Open-Label EMERGENT-5 Trial
- Patient Satisfaction with Xanomeline and Trospium Chloride Treatment for Schizophrenia: A Qualitative Interview-Based Study
- Changes in Quality of Life for Schizophrenia Outpatients Receiving the Muscarinic Agonist Xanomeline and Trospium: Findings of a Qualitative Interview-Based Study
HEOR:
- Negative symptoms and cognitive impairment in US patients with schizophrenia: a real-world descriptive study using the NeuroBlu database
- Comparative Efficacy, Safety, and Tolerability of Xanomeline and Trospium Chloride versus Eight Atypical Antipsychotics for the Acute Treatment of Adults with Schizophrenia – A Network Meta-Analysis
- Current Estimates of the Incidence and Prevalence of Schizophrenia in the U.S.
A full list of Bristol Myers Squibb presentations at Psych Congress is below. All presentations will take place in the Exhibit Hall on Thursday, October 31 and Friday, November 1 from 1:30 – 3:00 p.m. ET. For more information, please visit the Psych Congress website here.
| Abstract Title | Primary Author | Type |
| Clinical Data | ||
| Long-Term Safety and Efficacy of Xanomeline and Trospium Chloride in Schizophrenia: Results from the 52-Week, Open-Label EMERGENT-4 Trial | Kaul, I. | Poster |
| Long-Term Safety, Tolerability, and Efficacy of Xanomeline and Trospium Chloride in People with Schizophrenia: Results From the 52-Week, Open-Label EMERGENT-5 Trial | Kaul, I. | Poster |
| Patient Satisfaction with Xanomeline and Trospium Chloride Treatment for Schizophrenia: A Qualitative Interview-Based Study | Horan, W. | Poster |
| Changes in Quality of Life for Schizophrenia Outpatients Receiving the Muscarinic Agonist Xanomeline and Trospium: Findings of a Qualitative Interview-Based Study | Weiden, P. | Poster |
| Efficacy of Xanomeline and Trospium Chloride in Schizophrenia: Post Hoc Analyses of Data Pooled From Three 5-Week, Randomized, Double-Blind, Placebo-Controlled EMERGENT Trials | Kaul, I. | Poster |
| Xanomeline and Trospium Chloride for the Treatment of Agitation in Schizophrenia: PANSS-EC Results From Three Randomized, Double-Blind, Placebo-Controlled Trials | Yeung, P. | Poster |
| Long-Term Metabolic Outcomes Associated With Xanomeline and Trospium Chloride: Interim Results From Pooled, Long-Term Safety Studies EMERGENT-4 and EMERGENT-5 | Claxton, A. | Poster |
| Assessing Participant Experience With Xanomeline and Trospium Chloride Treatment Using In-Trial Qualitative Interviews: Perceived Effect on Symptoms During a Long-Term Phase 3 Trial in Schizophrenia | Horan, W. | Poster |
| Health Economics and Outcomes Research | ||
| Negative symptoms and cognitive impairment in US patients with schizophrenia: a real-world descriptive study using the NeuroBlu database | Lipunova, N., Holmusk Technologies, Inc. | Poster |
| Comparative Efficacy, Safety, and Tolerability of Xanomeline and Trospium Chloride versus Eight Atypical Antipsychotics for the Acute Treatment of Adults with Schizophrenia – A Network Meta-Analysis | Hickey, C., Lumanity | Poster |
| Current Estimates of the Incidence and Prevalence of Schizophrenia in the U.S. | Cajigal, A. | Poster |
